Page 1340 - Hematology_ Basic Principles and Practice ( PDFDrive )

1186 Part VII Hematologic Malignancies

13. Valent P, Sotlar K, Sperr WR, et al: Refined diagnostic criteria and clas- 22. Schwaab J, Schnittger S, Sotlar K, et al: Comprehensive mutational
sification of mast cell leukemia (MCL) and myelomastocytic leukemia profiling in advanced systemic mastocytosis. Blood 122(14):2460–2466,
(MML): a consensus proposal. Ann Oncol 25(9):1691–1700, 2014. 2013.
14. Georgin-Lavialle S, Lhermitte L, Dubreuil P, et al: Mast cell leukemia. 23. Maric I, Robyn J, Metcalfe DD, et al: KIT D816V-associated systemic
Blood 121(8):1285–1295, 2013. mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated
15. Valent P, Akin C, Arock M, et al: Definitions, criteria and global chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol
classification of mast cell disorders with special reference to mast cell 120(3):680–687, 2007.
activation syndromes: a consensus protocol. Int Arch Allergy Immunol 24. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al: KIT muta-
157(3):215–225, 2012. tion in mast cells and other bone marrow haematopoietic cell lineages
16. Escribano L, Diaz-Augustin B, López A, et al: Immunophenotypic in systemic mast cell disorders: a prospective study of the Spanish
analysis of mast cells in mastocytosis: when and how to do it. Proposals Network on Mastocytosis (REMA) in a series of 113 patients. Blood
of the Spanish Network on Mastocytosis (REMA). Cytometry B Clin 108(7):2366–2372, 2006.
Cytom 58(1):1–8, 2004. 25. Pardanani A: Systemic mastocytosis in adults: 2015 update on diagnosis,
17. Sotlar K, Cerny-Reiterer S, Petat-Dutter K, et al: Aberrant expression of risk stratification, and management. Am J Hematol 90(3):250–262, 2015.
CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol 26. Barete S, Lortholary O, Damaj G, et al: Long-term efficacy and safety
24(4):585–595, 2011. of cladribine (2-CdA) in adult patients with mastocytosis. Blood
18. Schwartz LB, Sakai K, Bradford TR, et al: The alpha form of human 126(8):1009–1016, 2015.
tryptase is the predominant type present in blood at baseline in normal 27. Akin C, Fumo G, Yavuz AS, et al: A novel form of mastocytosis associ-
subjects and is elevated in those with systemic mastocytosis. J Clin Invest ated with a transmembrane c-kit mutation and response to imatinib.
96(6):2702–2710, 1995. Blood 103(8):3222–3225, 2004.
19. Valent P, Escribano L, Broesby-Olsen S, et al: Proposed diagnostic algo- 28. Gotlib J, Kluin-Nelemans HC, George TI, et al: Efficacy and safety
rithm for patients with suspected mastocytosis: a proposal of the Euro- of midostaurin in advanced systemic mastocytosis. N Engl J Med
pean Competence Network on Mastocytosis. Allergy 69(10):1267–1274, 374(26):2530–2541, 2016.
2014. 29. Ustun C, Reiter A, Scott BL, et al: Hematopoietic stem-cell transplanta-
20. Nagata H, Worobec AS, Oh CK, et al: Identification of a point mutation tion for advanced systemic mastocytosis. J Clin Oncol 32(29):3264–3274,
in the catalytic domain of the protooncogene c-kit in the peripheral blood 2014.
mononuclear cells of patients who have mastocytosis with an associated 30. Gotlib J, Pardanani A, Akin C, et al: International Working Group-
hematologic disorder. Proc Natl Acad Sci USA 92(23):10560–10564, Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
1995. & European Competence Network on Mastocytosis (ECNM)
21. Arock M, Sotlar K, Akin C, et al: KIT mutation analysis in mast cell consensus response criteria in advanced systemic mastocytosis. Blood
neoplasms: recommendations of the European Competence Network on 121(13):2393–2401, 2013.
Mastocytosis. Leukemia 29:1223, 2015.